How many insider trades does FilingIQ track for ENTX?

FilingIQ tracks 75 Form 4 insider transactions for ENTX (Entera Bio Ltd.), covering filings from Jan 13, 2022 onwards. 5 of those were filed in the last 90 days.

Are ENTX insiders net buyers or net sellers?

Across the full Form 4 history for ENTX, 37 transactions (49%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ENTX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ENTX in?

Entera Bio Ltd. (ENTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $64.66M.

ENTX insider trading

Healthcare

Entera Bio Ltd. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

49% / 0%

Market cap

$64.66M

About Entera Bio Ltd.

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.

Company website: www.enterabio.com

ENTX insider activity at a glance

FilingIQ has scored 75 insider transactions for ENTX since Jan 13, 2022. The most recent filing in our index is dated May 7, 2026.

Across the full history, 37 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ENTX insider trades is 63.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ENTX trades on FilingIQ Raw filings on SEC EDGAR

Latest ENTX Form 4 filings

Toledano Miranda Jayne Chief Executive Officer

P Dec 22, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for ENTX?: FilingIQ tracks 75 Form 4 insider transactions for ENTX (Entera Bio Ltd.), covering filings from Jan 13, 2022 onwards. 5 of those were filed in the last 90 days.
Are ENTX insiders net buyers or net sellers?: Across the full Form 4 history for ENTX, 37 transactions (49%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ENTX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ENTX in?: Entera Bio Ltd. (ENTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $64.66M.

Methodology & sources

Every ENTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.